Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Vensana Capital I GP, LLC; Klein Peter Justin; Vensana Capital I, L.P.; Nielsen Kirk G. | 10% owner | SpyGlass Pharma, Inc.SGP | BuyP · Open-market or private purchase | 165,000 | $16.00 | $2,640,000 | 3,310,619Indirect, See footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Vensana Capital I GP, LLC; Klein Peter Justin; Vensana Capital I, L.P.; Nielsen Kirk G. | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 359,255 | Not reported | No price reported | 3,145,619Indirect, See footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Vensana Capital I GP, LLC; Klein Peter Justin; Vensana Capital I, L.P.; Nielsen Kirk G. | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 548,067 | Not reported | No price reported | 2,786,364Indirect, See footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Vensana Capital I GP, LLC; Klein Peter Justin; Vensana Capital I, L.P.; Nielsen Kirk G. | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 548,067 | Not reported | No price reported | 2,238,297Indirect, See footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Vensana Capital I GP, LLC; Klein Peter Justin; Vensana Capital I, L.P.; Nielsen Kirk G. | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 1,690,230 | Not reported | No price reported | 1,690,230Indirect, See footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Nielsen Kirk G. | Director | SpyGlass Pharma, Inc.SGP | BuyP · Open-market or private purchase | 165,000 | $16.00 | $2,640,000 | 3,310,619Indirect, See Footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Nielsen Kirk G. | Director | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 359,255 | Not reported | No price reported | 3,145,619Indirect, See Footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Nielsen Kirk G. | Director | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 548,067 | Not reported | No price reported | 2,786,364Indirect, See Footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Nielsen Kirk G. | Director | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 548,067 | Not reported | No price reported | 2,238,297Indirect, See Footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Nielsen Kirk G. | Director | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 1,690,230 | Not reported | No price reported | 1,690,230Indirect, See footnote | Form 4 filed 10 Feb 2026, on sec.gov (opens in a new tab)Filed 10 Feb 2026 | |
| Makhzoumi Mohamad | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 402,273 | Not reported | No price reported | 1,357,263Indirect, See Note 3 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Makhzoumi Mohamad | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 954,990 | Not reported | No price reported | 954,990Indirect, See Note 3 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Makhzoumi Mohamad | 10% owner | SpyGlass Pharma, Inc.SGP | BuyP · Open-market or private purchase | 937,500 | $16.00 | $15,000,000 | 6,035,038Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Makhzoumi Mohamad | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 737,962 | Not reported | No price reported | 5,097,538Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Makhzoumi Mohamad | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 1,370,168 | Not reported | No price reported | 4,359,576Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Makhzoumi Mohamad | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 1,370,168 | Not reported | No price reported | 2,989,408Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Makhzoumi Mohamad | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 1,619,240 | Not reported | No price reported | 1,619,240Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Yang Rick | 10% owner | SpyGlass Pharma, Inc.SGP | BuyP · Open-market or private purchase | 937,500 | $16.00 | $15,000,000 | 6,035,038Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Yang Rick | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 737,962 | Not reported | No price reported | 5,097,538Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Yang Rick | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 1,370,168 | Not reported | No price reported | 4,359,576Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Yang Rick | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 1,370,168 | Not reported | No price reported | 2,989,408Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Yang Rick | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 1,619,240 | Not reported | No price reported | 1,619,240Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Walker Paul Edward | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 402,273 | Not reported | No price reported | 1,357,263Indirect, See Note 3 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Walker Paul Edward | 10% owner | SpyGlass Pharma, Inc.SGP | OtherC · Conversion of a derivative security | 954,990 | Not reported | No price reported | 954,990Indirect, See Note 3 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 | |
| Walker Paul Edward | 10% owner | SpyGlass Pharma, Inc.SGP | BuyP · Open-market or private purchase | 937,500 | $16.00 | $15,000,000 | 6,035,038Indirect, See Note 2 | Form 4 filed 11 Feb 2026, on sec.gov (opens in a new tab)Filed 11 Feb 2026 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.